UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(A) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(a)
MEDICAL TECHNOLOGY SYSTEMS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock Par Value $.01
--------------------------------------------------------------------------------
(Title of Class of Securities)
58462R505
--------------------------------------------------------------------------------
(CUSIP Number)
Richard M. Lilly
2424 North Federal Highway, Suite 311
Boca Raton, Florida 33421
(561) 391-4222
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
August 2, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [_].
<PAGE>
SCHEDULE 13D
CUSIP No. 58462R505 Page 2 of 6 Pages
________________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
RICHARD M. LILLY
###-##-####
________________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3 SEC USE ONLY
________________________________________________________________________________
4 SOURCE OF FUNDS*
PF
________________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [_]
________________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
________________________________________________________________________________
7 SOLE VOTING POWER
336,100 shares of common stock
NUMBER OF
SHARES _________________________________________________________________
8 SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY
_________________________________________________________________
EACH 9 SOLE DISPOSITIVE POWER
336,100 shares of common stock
REPORTING
PERSON _________________________________________________________________
10 SHARED DISPOSITIVE POWER
WITH 0
________________________________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
336,100 shares of common stock
________________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Approximately 5.1% of the issued and outstanding common stock.
________________________________________________________________________________
14 TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
SCHEDULE 13D
CUSIP No. 58462R505 Page 3 of 6 Pages
ATTACHMENT
________________________________________________________________________________
Item 1. Security and Issuer.
Common stock, par value $.01
Medical Technology Systems, Inc.
12920 Automobile Boulevard
Clearwater. Florida 33762
________________________________________________________________________________
Item 2. Identity and Background.
(a) Name: Richard M. Lilly (Richard M. Lilly Revocable Trust)
(b) Business Address: 2424 North Federal Highway, Suite 311
Boca Raton, Florida 33431
(c) Principal Occupation:
Mr. Lilly is an investment banker with Indianapolis Securities, Inc. a
registered broker-dealer whose office is set forth in (b) above.
(d) Mr. Lilly, during the last five years, has not been convicted in a
criminal proceeding.
(e) Mr. Lilly, during the last five years, was not a party to a civil
proceeding of a judicial or administrative body of competent
jurisdiction which as a result of such proceeding was subject to a
judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws.
(f) Citizenship: United States
________________________________________________________________________________
Item 3. Source and Amount of Funds or Other Consideration.
Personal funds in the aggregate amount of $151,296.
<PAGE>
________________________________________________________________________________
Item 4. Purpose of Transaction.
Mr. Lilly has obtained his shares principally for investment purposes. However,
he will continue to evaluate the Company and its current management and reserve
options as to any future actions he may take. He has preliminarily reviewed the
proposed recapitalization plan announced on July 31, 2000 and does not believe
such plan is in the best interest of the Company or its shareholders. However,
Mr. Lilly does not presently intend to solicit proxies for opposition to such
plan at its scheduled annual meeting.
________________________________________________________________________________
Item 5. Interest in Securities of the Issuer.
(a) 336,100 shares of common stock, constituting approximately 5.1% of the
issued and outstanding common stock.
(b) There is sole power to vote or to direct the vote and sole power to
dispose or to direct the disposition of the 336,100 shares of common
stock held by the Reporting Person.
(c) Set forth below is a list of the transactions of the Reporting Person
during the last 60 days. The transactions were brokerage transactions.
Mr. Lilly obtained his additional shares at various times from
July 24, 1998 at prices from $0.3164 and $0.4952.
Trade Date Settlement Date Quantity Price Net Amount
--------------------------------------------------------------------------
June 16, 2000 June 21, 2000 25,500 0.5366 13,683.39
June 21, 2000 June 26, 2000 20,500 0.5679 11,642.25
June 23, 2000 June 28, 2000 5,500 0.6621 3,641.38
June 26, 2000 June 29, 2000 1,000 0.6345 634.50
June 29, 2000 July 5, 2000 10,000 0.6305 6,304.50
July 6, 2000 July 11, 2000 550 0.6382 351.00
July 10, 2000 July 13, 2000 3,950 0.6311 2,493.00
July 11, 2000 July 14, 2000 200 0.6525 130.50
July 18, 2000 July 21, 2000 10,500 0.6304 6,619.50
July 24, 2000 July 27, 2000 4,200 0.6952 2,920.00
July 26, 2000 July 31, 2000 10,500 0.6617 6,947.63
July 26, 2000 July 31, 2000 5,000 0.6613 3,306.26
August 1, 2000 August 4, 2000 15,000 0.6293 9,439.50
(d) No other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of
such securities.
(e) Not applicable.
2
<PAGE>
________________________________________________________________________________
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
None
________________________________________________________________________________
Item 7. Material to be Filed as Exhibits.
None
________________________________________________________________________________
3
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this Statement on Schedule 13D is
true, complete and correct as of the date hereof.
Dated: August 10, 2000
/s/ Richard M. Lilly
----------------------------------------
Richard M. Lilly
Attention. Intentional misstatements or omissions of fact constitute federal
criminal violations (see 18 U.S.C. 1001).
4
